Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
$11.47
$2.66
$32.75
$48.64M2.5795,409 shs43,300 shs
Cerecor Inc. stock logo
CERC
Cerecor
$10.66
-2.1%
$2.60
$1.98
$4.50
$1.02B1.441.27 million shs117,034 shs
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
$0.00
$0.02
$9K0.859,482 shs110 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.23
-1.6%
$1.30
$1.13
$2.55
N/A0.4363,919 shs20,725 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
0.00%0.00%0.00%0.00%0.00%
Cerecor Inc. stock logo
CERC
Cerecor
-1.27%+7.09%+16.24%+124.79%+34.32%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%0.00%0.00%0.00%-97.78%
MediciNova, Inc. stock logo
MNOV
MediciNova
-1.60%-4.65%-3.15%-7.52%-37.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
$11.47
$2.66
$32.75
$48.64M2.5795,409 shs43,300 shs
Cerecor Inc. stock logo
CERC
Cerecor
$10.66
-2.1%
$2.60
$1.98
$4.50
$1.02B1.441.27 million shs117,034 shs
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
$0.00
$0.02
$9K0.859,482 shs110 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.23
-1.6%
$1.30
$1.13
$2.55
N/A0.4363,919 shs20,725 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
0.00%0.00%0.00%0.00%0.00%
Cerecor Inc. stock logo
CERC
Cerecor
-1.27%+7.09%+16.24%+124.79%+34.32%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%0.00%0.00%0.00%-97.78%
MediciNova, Inc. stock logo
MNOV
MediciNova
-1.60%-4.65%-3.15%-7.52%-37.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
0.00
N/AN/AN/A
Cerecor Inc. stock logo
CERC
Cerecor
0.00
N/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00
N/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
3.00
Buy$7.00469.11% Upside

Current Analyst Ratings Breakdown

Latest MNOV, EVLO, CERC, and AGLE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
8/27/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$9.00
7/24/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$9.00
6/16/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuyStrong-Buy$6.00 ➝ $5.00
(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
$2.33M0.00N/AN/A($60.61) per share0.00
Cerecor Inc. stock logo
CERC
Cerecor
$6.70M152.68N/AN/A$0.22 per share48.43
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
$1MN/AN/AN/A$1.07 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/A
Cerecor Inc. stock logo
CERC
Cerecor
-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$114.53MN/A0.00N/AN/AN/AN/A11/24/2025 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$11.04M-$0.25N/AN/AN/AN/A-23.12%-21.85%11/12/2025 (Estimated)

Latest MNOV, EVLO, CERC, and AGLE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.07-$0.07N/A-$0.07N/A$0.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/AN/AN/AN/AN/A
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/A
4.59
4.59
Cerecor Inc. stock logo
CERC
Cerecor
0.79
2.19
2.18
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
13.26
13.26

Institutional Ownership

CompanyInstitutional Ownership
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/A
Cerecor Inc. stock logo
CERC
Cerecor
62.84%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.31%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%

Insider Ownership

CompanyInsider Ownership
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
6.60%
Cerecor Inc. stock logo
CERC
Cerecor
45.70%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
1.02%
MediciNova, Inc. stock logo
MNOV
MediciNova
13.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
694.05 million3.78 millionOptionable
Cerecor Inc. stock logo
CERC
Cerecor
3196.01 millionN/ANot Optionable
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
12018.98 million18.79 millionNo Data
MediciNova, Inc. stock logo
MNOV
MediciNova
10N/AN/AOptionable

Recent News About These Companies

MediciNova Provides Shareholder Update on Key Developments
MediciNova: Q2 Earnings Snapshot

Media Sentiment Over Time

Aeglea BioTherapeutics stock logo

Aeglea BioTherapeutics NASDAQ:AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Cerecor stock logo

Cerecor NASDAQ:CERC

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Evelo Biosciences stock logo

Evelo Biosciences NASDAQ:EVLO

$0.0005 0.00 (0.00%)
As of 09/12/2025

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.23 -0.02 (-1.52%)
As of 09/12/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.